Outpatient antibiotic use in British Columbia, Canada: reviewing major trends since 2000

Ariana Saatchi1, Andrew M. Morris2, David M. Patrick3,4, James McCormack1, Romina C. Reyes5,6, Phillip Morehouse5, Jennifer Reid7, Salimah Shariff7, Marcus Povitz8, Michael Silverman9 and Fawziah Marra10

1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Sinai Health System, University Health Network and University of Toronto, Toronto, ON, Canada; 3British Columbia Centre for Disease Control, Vancouver, BC, Canada; 4School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; 5LifeLabs, Vancouver, BC, Canada; 6Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; 7ICES, Western University, London, ON, Canada; 8Department of Medicine, University of Calgary, Calgary, AB, Canada; 9Faculty of Medicine, University of Western Ontario, London, ON, Canada

*Corresponding author. E-mail: fawziah@mail.ubc.ca

Received 4 May 2021; accepted 6 July 2021

Background: With 90% of all antibiotics in Canada being used in the community setting, tracking outpatient prescribing is integral to mitigate the issue of antimicrobial resistance. In 2005, a provincial programme was launched in British Columbia (BC) to disseminate information regarding the judicious use of antibiotics. These efforts include educational campaigns, updated practitioner guidelines and academic detailing. The impact of provincial stewardship on community prescribing requires ongoing evaluation.

Objectives: This study examines outpatient prescribing to quantify rates of antibiotic use, evaluate major trends over time and identify new targets for stewardship.

Methods: A retrospective cohort design using population-level data.

Results: This study included over 3.5 million unique individuals with a total of 51,367,938 oral antibiotic prescriptions dispensed over a 19 year period (2000–18). Overall antibiotic utilization decreased by 23% over the course of the study period. This trend in the reduction of antibiotic prescription was observed across all major antibiotic classes, apart from the class of other antibacterials, which was mostly related to use of nitrofurantoin. The largest magnitudes of decreased prescribing were observed in the paediatric population. Prescribing across two distinct eras of provincial stewardship reaffirmed preliminary findings of programme efficacy, when compared with pre-stewardship levels of antibiotic use.

Conclusions: Outpatient prescribing in BC is decreasing overall, and this study confirms an association between provincial stewardship interventions and improvements in antibiotic use. Pronounced declines in paediatric populations are promising, and further research is underway to examine prescribing quality.

Introduction

Antimicrobials remain among the most prescribed medications in Canada. It is imperative to understand outpatient prescribing as over 90% of antibiotics are prescribed in the community setting. Identifying suboptimal or unnecessary use of these essential medications is vital, as antimicrobial resistance (AMR) continues to jeopardize the future efficacy of these essential medications. In British Columbia (BC), efforts to reduce use of antimicrobials have included: educational campaigns, practitioner guidelines and frequent academic detailing. The latter is a programme by the Ministry of Health that provides evidence-based drug information on the best prescribing practices to primary care physicians. The Community Antimicrobial Stewardship (CAS) programme has been in operation provincially since 2005 educating the public on judicious antibiotic use and encouraging stewardship through the Do Bugs Need Drugs (DBND) campaign. A complementary programme arm works to educate healthcare professionals through accredited courses on antibiotic use, resistance and strategies to prescribe appropriately, and to disseminate timely guidelines and other resources.
Misusing antimicrobials is a primary mechanism driving resistance, and overuse has been associated with increased adverse events and higher financial burdens. In 2018, longer hospital stays, lengthier courses of treatment and other expenses attributable to AMR cost the Canadian healthcare system $1.4 billion.

Multiple studies have examined prescribing for specific indications and identified respiratory tract infections to be amongst the highest associated diagnoses. Upper respiratory tract infections, sore throat, acute cough, sinusitis, common cold and acute bronchitis—all of which are predominantly caused by viruses—are routinely prescribed antimicrobials at high rates, despite incurring no benefit. It is vital to understand outpatient prescribing patterns as increased community use has been associated with rising resistance across both outpatient and inpatient healthcare settings.

Moreover, correlations between inpatient prescribing and associated rates of resistance are weak, which suggests that selection caused by community prescribing may be a primary force underlying rates of resistance.

This retrospective cohort study was conducted to evaluate antibiotic use in BC, Canada—at the population level. The objectives of this study were to evaluate prescribing of antimicrobials in outpatient care, identify common agents and indications and examine the relative impact of a formalized provincial stewardship programme on antibiotic use.

Methods and methods

Data sources

In Canada, public health insurance is available to eligible residents. Canadian citizens and permanent residents can apply for provincial health insurance. The Ministry of Health in British Columbia houses several healthcare-related databases, which have comprehensive information on BC residents (population: 5 million). Antibiotic information was extracted from BC PharmaNet, a centralized data system that links all pharmacies with every prescription dispensed through community and hospital outpatient pharmacies. All antimicrobials are recorded in this system except those used for treatment of sexually transmitted infections and HIV, as well as medications administered within the hospitals/ emergency departments. The Medical Service Plan (MSP) billing system records all claims submitted by physicians for services provided to BC residents, including diagnostic codes. Data were extracted, anonymized and made available to researchers by Population Data BC. All inferences, opinions and conclusions drawn in this study are those of the authors and do not reflect the opinions or policies of the Data Steward(s).

Study population

Our study included all residents of BC from 1 January 2000 to 31 December 2018. Antibiotic dispensations were extracted from PharmaNet and then matched to the MSP system using anonymized patient identifiers. Antimicrobials were limited to oral and acute use only (continuous <30 day supply). A prescription and diagnosis were linked using an algorithm that matched the date on which the medication was dispensed to a practitioner service date within 5 days prior. If a practitioner service date was associated with more than one diagnostic code, or multiple service dates fell within a single 5 day period of a prescription dispensing date, then a three-tiered hierarchy was applied to link only the most relevant diagnostic code to the prescription. The tiers have been validated in several studies across the USA and Canada and essentially use the same concept, which is: tier 1 indications are those that always require antibiotic prescription; tier 2: sometimes require antibiotic prescription; and tier 3: antibiotics unnecessary. If multiple codes were present within a given linkage period then precedent was given to tier 1 diagnoses followed by tier 2, then 3. If multiple diagnoses were listed from the same tier, the primary physician code was selected for analysis. Prescriptions that did not match to an MSP record were classified as unlinked. Multiple prescriptions per subject were permitted in our analyses. All cells with n < 5 were excluded from subsequent analyses to preserve subject anonymity.

Antimicrobial stewardship eras

As the DBND programme launched in 2005, the pre-stewardship era captures 5 years of prescribing prior to any community interventions. Era I reflects the programme goals and initiatives at inception, which included community education on handwashing and the principles of antibiotic use for bacterial infection. During this period, prescribing for upper respiratory tract was the target for optimization with various materials, including updated guidelines and newsletters, disseminated to healthcare professionals. These materials communicated the issues of bacterial resistance and recommended the reservation of broad-spectrum antibiotics. Era II is built on the foundations laid in I, with a shift towards judicial urinary tract prescribing. Prescribing guidelines coupled with interventions across community and long-term care facility settings promoted the prescribing of first-line agents. Suboptimal prescribing in the wake of diagnostic uncertainty or the absence of lab confirmation for urinary tract infections was also discouraged.

Outcomes and statistical analyses

Antibiotics were classified based on the Anatomical Therapeutic Chemical (ATC) classification system developed by WHO. Consumption rates were calculated as prescriptions per 1000 population per year, using age and gender specific denominator estimates for the population from Statistics BC. MSP diagnostic codes are ordered by the ninth revision of the International Classification of Diseases developed by WHO, commonly referred to as ICD-9. Several indications were grouped within the classifications of upper respiratory tract infections (URTIs), acute otitis media (AOM), lower respiratory tract infections (LRTIs), urinary tract infections (UTIs) and skin/soft tissue infections (SSTIs).

Overall rates of total oral antibiotic use were examined and then stratified by seven major ATC classes and, subsequently, clinically relevant drugs. For each major ATC class, rates of use were further examined by sex, age group (0–2, 3–9, 10–18, 19–49, 50–64, 65–80 and ≥80 years) and indication.

Rate ratios (RR) for the above outcomes were estimated using Poisson regression to assess the impact of the BC provincial stewardship programme. Three time periods of interest were identified: pre-stewardship (2000–04), stewardship era I (2005–13) and stewardship era II (2014–18). Eras were delineated to complement relevant provincial interventions and targets over time.
Outpatient antibiotic use in BC

Overall and age-specific RR were calculated using annual count data with a population offset. Autocorrelation was evaluated using the Durbin–Watson test with values returned ~2 indicating no issue for serial correlation. A post hoc interrupted time series analysis was also undertaken to verify changes in overall antibiotic use over time, for all ages. All analyses were performed using SAS 9.4 and R version 3.3.1.

Results

An average of 1 374 222 unique patients were prescribed an antibiotic in any study year, with over 51 million total antibiotic prescriptions dispensed in the outpatient setting over the 19-year period (Table 1). The BC population grew by roughly 20% over the course of this study, from 4.03 million residents in 2000 to 5.00 million by 2018 (R < 0.05 based on linear regression). The mean annual age of our cohort also increased from 39 to 49 years of age by 2018. On average, about 31.1% (range 26.2%–33.7%) of BC residents were dispensed antibiotics in any study year, with a steady downward trend. Those individuals prescribed were commonly older females residing in urban settings. No differences were observed across income quintiles.

Table 1 Cohort characteristics

| Cohort characteristics (N) | Overall (2000–18) |
|----------------------------|------------------|
| Total number of patients   | 26 110 225       |
| Average patients per year  | 1 374 222        |
| Age                        |                  |
| 0–2                        | 769 903          |
| 3–9                        | 2 112 836        |
| 10–18                      | 2 362 166        |
| 19–49                      | 10 774 734       |
| 50–64                      | 5 232 075        |
| 65–79                      | 3 389 791        |
| ≥80                        | 1 468 720        |
| Income quintilea           |                  |
| quintile 1 (lowest)        | 5 332 067        |
| quintile 2                 | 5 220 283        |
| quintile 3                 | 5 073 879        |
| quintile 4                 | 4 984 898        |
| quintile 5 (highest)       | 4 780 620        |
| missingb                   | 718 478          |
| Rural/urban statusc        |                  |
| rural                      | 4 358 270        |
| urban                      | 20 610 581       |
| missingb                   | 1 141 374        |
| Total antibiotic prescriptions | 51 367 938   |
| Total prescriptions linkedd to indication | 36 526 088 |

Various population data BC-determined neighborhood income quintile (i.e. household size-adjusted measure of household income) using a postal code-based algorithm standardized by Statistics Canada.

bMissing represents absent or not applicable patient demographic information.

cRural status represents local population of 1000 to 29 999; urban status represents local population ≥30 000.

dLinked refers to an MSP entry ≤5 days of the dispensation date recorded in PharmaNet.

ePopulation Data BC-determined neighborhood income quintile (i.e. household size-adjusted measure of household income) using a postal code-based algorithm standardized by Statistics Canada.

Overall antibiotic utilization

Oral antibiotics were prescribed at an overall average rate of 609 prescriptions per 1000 population. Outpatient prescribing decreased by 23% over the study period from 652 to 503 prescriptions per 1000 population (Figure 1).

By major ATC class, antibiotic use varied over the study period. Figure 2 shows the details for consumption, by ATC class, between 2000 and 2018. Decreasing use was observed for penicillins (−27%), macrolides (−43%), other β-lactams (−12%), sulphonamides and trimethoprim (−58%) and quinolones (−22%). Tetracycline dispensations remained constant over the study period, while other antibacterials (J01X) increased in use by 97%. Nitrofurantoin drove this increase, ending the study period with 35 prescriptions per 1000 population in contrast to only 13 per 1000 population in 2000. Use of metronidazole, the second most prescribed J01X antibiotic, was consistent over the study period.

For penicillins (J01C), a decreasing trend was led by amoxicillin, which accounts for most prescriptions issued (range 169 to 126 prescriptions per 1000 population) and decreased in use by 25%. However, penicillin V (range 40 to 13 prescriptions per 1000 population) and cloxacillin (range 21 to 2 prescriptions per 1000 population) also declined by 2018 with 67.5% and 90.5% reduction, respectively.

Although macrolide use decreased overall, within the class there was a replacement of first-generation drugs by second-generation counterparts like azithromycin (range 13 to 32 prescriptions per 1000 population), which increased 146.2% in lieu of first-generation erythromycin, which decreased by 97.0% with only 2 prescriptions per 1000 population by 2018. Tetracycline antibiotics remained steady in use overall, however, doxycycline increased by 94.4% (range 14 to 35 prescriptions per 1000 population). This increase was offset by declines in use of both tetracycline (−80.0%) and minocycline (−33.3%), establishing a net stability for the class.

When stratified by age, disparate patterns in use are apparent (Figure 3). Total antibiotic use decreased across all paediatric categories (0–2 years: −60.0%; 3–9 years: −51.0%; 10–18 years: −47.2%), as well as in adults between 19 and 49 years of age (−30.5%). The sharpest declines were seen in our youngest cohorts, with a negative association between increasing age and decreasing magnitude of antibiotic reduction. Individuals aged 50–64 years saw an increase of 8.1% by 2018, while those aged 65–79 years resumed the downward trend with a 10.6% decline by 2018. Those above 80 years were prescribed at rates far above other age groups and remained steady over the study period (range 1021 to 1178 prescriptions per 1000 population).

Antibiotic utilization by indication

In any given study year, URTI was the most commonly linked category of diagnoses (range 75 to 148 prescriptions per 1000 population) (Figure 4). Use within this category was driven by prescriptions for acute bronchitis (range 16 to 33 prescriptions per 1000 population) and acute upper respiratory tract unspecified
Overall, prescribing for URRT decreased by 49% with 75 prescriptions per 1000 population in 2018, the highest rate that year for any category of indication. The second most common indication was UTI (range 48 to 53 prescriptions per 1000 population) (Figure S3). In contrast to URTI, UTI increased by 10% over the study period with cystitis driving this trend (range 31 to 36 prescriptions per 1000 population) (Figure S4). LRTI antibiotic use also increased (50%) over the study period, however, the magnitude of prescribing remained well below all other indications, apart from AOM (Figure S5). By 2018, LRTI diagnoses were dispensed at a rate of 15 prescriptions per 1000 population (Figure S6).

Parallel to URTI, declines in prescribing were also observed for AOM and SSTI diagnoses (Figures S7 and S8). Prescribing for supplicative and unspecified otitis media decreased by 71% over the study period with only 9 prescriptions per 1000 population in 2018. Moreover, prescribing for this indication was heavily swayed within paediatric age categories. By the end of the study period, SSTI diagnoses decreased by 24%, with most prescriptions issued for other cellulitis and abscess (range 17 to 20 prescriptions per 1000 population) or symptoms involving skin and other integumentary tissue (range 8 to 16 prescriptions per 1000 population) (Figure S9).

**Eras of stewardship**

Prescribing for common infections in BC decreased overall in both eras of stewardship when compared with pre-stewardship levels of antibiotic use (Tables S1 and S2). Era I saw a 4% decline overall (RR 0.96, 95% CI 0.96–0.97) with a 24% decrease in era II (RR 0.76, 95% CI 0.76–0.76) when compared with pre-stewardship prescribing. The largest magnitudes of change were observed in paediatric populations with children aged 0–2 years prescribed 54% less (RR 0.46, 95% CI 0.46–0.46) by era II. A negative association was identified between increasing age and magnitude of decrease. Children aged 3–9 and those aged 10–18 years saw a 48% (RR 0.52, 95% CI 0.52–0.52) and 42% (RR 0.58, 95% CI 0.58–0.58) decrease in prescribing, respectively, in comparison to pre-stewardship levels. These paediatric age groups all experienced significant declines in era I as well, when compared with the pre-stewardship period (Table 2).

Changes in adult populations varied by age group, with our most senior age category, ≥80 years, experiencing increases in antibiotic use in both stewardship eras, when compared with pre-stewardship levels (era I: RR 1.17, 95% CI 1.17–1.18; era II: RR 1.12, 95% CI 1.11–1.12). Individuals aged 50–64 and 65–79 years saw minor increases in era I, when compared with pre-stewardship antibiotic use, however, adults between the ages of 19 and 49 years saw no significant changes in prescribing for era I. By contrast, in era II all adult age groups decreased in prescribing apart
from our most senior category as described above. As in paediatrics, a negative association was identified between increasing age and magnitude of changes in prescribing.

Discussion

Over a 19 year study period, more than 51 million prescriptions for antibiotics were dispensed, and by 2018 prescribing had decreased by 23.1% across the province. This downward trend was most pronounced for those aged between 0 and 49 years. In contrast, increases in prescribing rates were identified in those aged 65 years and above, while our eldest cohort of ≥80 years remained steady throughout the study period. As our cohort included an average of 1 374 222 unique patients in any given study year, the corresponding average of 2.7 million prescriptions per annum suggests that some individuals received multiple prescriptions, either through repeat clinician visits or multiple prescriptions per visit.

Notwithstanding an overall decrease in use, URTIs persist as the most prescribed indication in 2018, despite their self-limiting nature, viral aetiology and absence of guideline recommendations. Moreover, β-lactams and macrolides were the most prescribed classes across the study period. These findings suggest that some individuals received multiple prescriptions, either through repeat clinician visits or multiple prescriptions per visit.

The prevalence of respiratory tract diagnoses as leading recipients of inappropriate or unnecessary antibiotic prescriptions has been corroborated across multiple geographic regions. Fleming-Dutra et al. (2016) identified sinusitis as the most prescribed indication in US ambulatory care. Regions of lower prescribing were not found to experience increased adverse consequences due to potential under treatment, moreover, residual levels of overprescribing were found. In Ontario (ON), another Canadian province, respiratory tract infections were again identified as the most prescribed category of indication. Another ON study found approximately 25% of antibiotic prescribing either unnecessary or suboptimal across all indications. With respect to URTI, bronchitis led inappropriate prescribing, with 52% of bronchitis-associated antibiotics issued unnecessarily. Further investigation is underway to examine the quality of prescribing in terms of appropriate, suboptimal and inappropriate/unnecessary use in order to compare BC quality with other health authorities.

The plateau in antibiotic use observed in our eldest cohort is not unique to BC, with other regions having reported similar elevated rates. As this sub-population is especially vulnerable to adverse events and are more likely to experience concurrent comorbidities, delineating rates of overuse or misuse of antibiotics for older adults in BC is integral to calibrate stewardship interventions. Despite the positive implications of a decreasing trend overall, and the success achieved within BC paediatric populations, the failure to curb prescribing to those aged ≥65 years requires urgent intervention as the misuse of antibiotics within this population confers
far greater patient risk. The risk posed relates to the ongoing contribution of antimicrobial misuse to bacterial resistance but also related to potential antibiotic-related adverse events, including *Clostridioides difficile*.

In 2016, it was reported that 30% of all antibiotic use in US ambulatory care is inappropriate. Similar studies on prescribing quality in BC are underway, however, a paper from Hersh et al. (2021) corroborates the age-specific trends reported here. Hersh et al. describe immobility in quality of antibiotic use for adult populations with a concerning 2% decrease reported over a 5-year period. However, pediatrics has experienced a 41% relative reduction with optimizations attributed to stewardship interventions, including educational campaigns and updated clinical guidelines. Improvements in quality for US outpatient prescribing have been tied to antibiotics used to treat acute respiratory infections. Relatedly, prescribing for these infections in BC was found to have declined by 39% (RR 0.61) by 2018, with even more pronounced reductions for children (Table S2).

As reported by Glass-Kaastra et al. (2014), prescribing in BC reflects some of the most conservative rates of antibiotic use in Canada. Following an internal review, the CAS programme has been found to have consistently met programme goals and objectives in disseminating critical information across the province. At time of publication, McKay et al. stipulated that further efforts were necessary to achieve clear population-level effects.

This study has limitations inherent to all retrospective studies using administrative health data. As the nature of our data prevents nested analyses, multiple prescriptions were permitted per individual, and our standard error may be biased. Further, our rates do not account for unfilled prescriptions issued, and levels of compliance to dispensed medications are unknown. Records of indications are reliant on accurate coding by billing physicians. However, it is notable that Canadian primary-care physician claims data have a high positive-predictive value for diagnosis of common infections including acute non-bacterial URTIs (0.84, 95% CI 0.81–0.88). Further, as lab data did not confirm the presence of infection and comorbidity data were unavailable, our use of ICD-9 codes may be subject to misclassification bias.

**Conclusions**

Since 2000, the landscape of antimicrobial use has changed in BC, with a community antimicrobial stewardship programme working to disseminate provincial stewardship materials and promote a cultural shift towards the judicious use of antibiotics. Although this study cannot attribute causation, a substantial decline in antibiotic use has been observed in BC.
use was observed in our 19 year study period, with temporal correlations between targeted stewardship eras and related optimizations in antibiotic use. Despite this progress, prescribing in our eldest cohorts is increasing, and optimizing prescribing to our most vulnerable population remains a provincial target. Moreover, URTIs are routinely prescribed in the wake of substantial evidence that antimicrobials do not confer a benefit against these self-limiting indications. Further research efforts to characterize the quality of prescriptions issued in BC, to complement the quantity in use examined here, are underway.

Acknowledgements
We would like to acknowledge Population Data BC and LifeLabs for providing all health administrative data for this project.
Funding
This work was supported by a Canadian Institutes of Health Research (CIHR) project grant (201809-408648).

Transparency declarations
Population Data BC subsidized funding for the data that were required for A.S.’s doctoral thesis project. The remainder of the data acquisition costs and a portion of A.S.’s salary were covered by the Canadian Institutes of Health Research project grant.

Author contributions
A.S. conceptualized the study under the guidance of F.M.; conducted the literature review, data cleaning, analysis and interpretation; and wrote the initial draft. A.S. drafted antibiotic case capture code and reviewed the manuscript. J.R. and S.S. provided guidance on confounding adjustment and sensitivity analyses. All authors provided critical feedback on data interpretation and the final draft of the manuscript.

Disclaimer
All inferences, opinions and conclusions drawn in this research are those of the authors and do not reflect the opinions or policies of the Data Steward(s) from Population Data BC.

Supplementary data
Tables S1 and S2 and Figures S1 to S9 are available as Supplementary data at JAC-AMR Online.

References
1 Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System 2017 Report—Executive Summary. https://www.canada.ca/en/public-health/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-2017-report-executive-summary.html.
2 Do Bugs Need Drugs? Educational Resources. http://www.dobugsneeddrugs.org/educational-resources/.
3 Do Bugs Need Drugs? http://www.dobugsneeddrugs.org/.
4 McKay RM, Vrbova L, Fuertes E et al. Evaluation of the Do Bugs Need Drugs? program in British Columbia: can we curb antibiotic prescribing? Can J Infect Dis Med Microbiol 2011; 22: 19–24.
5 Smith R, Coast J. The true cost of antimicrobial resistance. BMJ 2013; 346: f1493.
6 Shehab N, Patel PR, Sririvasan A et al. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47: 735–43.
7 Suda KJ, Hicks LA, Roberts RM et al. A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009. J Antimicrob Chemother 2013; 68: 715–8.
8 Finlay BB, Conly J, Coyte PC et al. When Antibiotics Fail: The Expert Panel on the Potential Socio-Economic Impacts of Antimicrobial Resistance in Canada. https://ccaco-reports.ca/reports/the-potential-socio-economic-impacts-of-antimicrobial-resistance-in-canada/.
9 McCaig LF, Besser RE, Hughes JM. Antimicrobial-drug prescription in ambulatory care settings, United States, 1992–2000. Emerg Infect Dis 2003; 9: 432–7.
10 van den Broek d’Obrenan J, Verheij TJM, Numans ME et al. Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatment. J Antimicrob Chemother 2014; 69: 1701–7.
11 Shulman ST, Bisno AL, Clegg HW et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55: e86–102.
12 Chow AW, Benninger MS, Brook I et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54: e72–112.
13 Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59: e10–52.
14 CDC. Appropriate Antibiotic Use: Antibiotic Use. https://www.cdc.gov/antibiotic-use/index.html.
15 Wang A, Daneman N, Tan C et al. Evaluating the relationship between hospital antibiotic use and antibiotic resistance in common nosocomial pathogens. Infect Control Hosp Epidemiol 2017; 38: 1457–63.
16 Sun L, Klein EY, Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis 2012; 55: 687–94.
17 British Columbia Ministry of Health [creator]. Medical Services Plan (MSP) Payment Information File. V2. Population Data BC [publisher]. Data Extract. MOH, 2011. http://www.podata.bc.ca/data.
18 British Columbia Ministry of Health [creator]. Consolidation File (MSP Registration & Premium Billing). V2. Population Data BC [publisher]. Data Extract. MOH, 2011. http://www.podata.bc.ca/data.
19 BC Ministry of Health [creator]. PharmaNet. V2. BC Ministry of Health [publisher]. Data Extract. Data Stewardship Committee, 2011. http://www.podata.bc.ca/data.
20 Population Data BC. Medical Services Plan Data Set. https://www.popdata.bc.ca/data/health/msp.
21 Fleming-Dutra KE, Hersh AL, Shapiro DJ et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016; 315: 1864–73.
22 Schwartz KL, Langford BJ, Daneman N et al. Unnecessary antibiotic prescribing in a Canadian primary care setting: a descriptive analysis using routinely collected electronic medical record data. CMAJ Open 2020; 8: E360–9.
23 Chua KP, Fischer MA, Linder JA. Appropriateness of outpatient antibiotic prescribing among privately insured US patients: IDC-10-CM based cross sectional study. BMJ 2019; 364: k5092.
24 Do Bugs Need Drugs? Kids. http://www.dobugsneeddrugs.org/kids/.
25 Physicians’ Newsletter, Summer 2009. https://www2.gov.bc.ca/gov/content/data/health/practitioner-pro/medical-services-plan/july_2009.pdf.
26 Sharma P. Evaluating BC Provincial Academic Detailing Service’s intervention on antibiotic prescribing for suspected urinary tract infections in British Columbia’s nursing homes. Msc Thesis. The University of British Columbia, 2019; doi:10.14288/1.0378708.
27 Ministry of Health. UTIs in Primary and Long Term Care: Province of British Columbia. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/utis-in-primary-and-long-term-care.
28 Understanding Asymptomatic Bacteriuria. https://www2.gov.bc.ca/gov/content/health/practitioner-prof/primary-academic-detailing-service/asymptomatic-bacteriuria-newsletter.pdf.
29 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment: 2011, 2010. http://www.whocc.no/file/earhive/publications/2011guidelines.pdf.
30 BC Stats. Population Estimates, Province of British Columbia. https://www2.gov.bc.ca/gov/content/data/statistics/people-population-community/population-estimates.
Outpatient antibiotic use in BC

31 Ministry of Health. Diagnostic Code Descriptions (ICD-9), Province of British Columbia. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/msp/physicians/diagnostic-code-descriptions-icd-9.

32 CDC. International Classification of Diseases, Ninth Revision (ICD-9), 2019. https://www.cdc.gov/nchs/icd/icd9.htm.

33 Silverman M, Povitz M, Sontrop JM et al. Antibiotic prescribing for nonbacterial acute upper respiratory infections in elderly persons. Ann Intern Med 2017; 166: 765–74.

34 Tan C, Graves E, Lu H et al. A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study. CMAJ Open 2017; 5: E878–85.

35 Wu JH-C, Langford B, Ha R et al. Defining appropriate antibiotic prescribing in primary care: a modified Delphi panel approach. JAMM! 2020; 5: 61–9.

36 Hersh AL, King LM, DJ, S et al. Unnecessary antibiotic prescribing in US ambulatory care settings, 2010-2015. Clin Infect Dis 2021; 72: 133–7.

37 Saha S, Kapoor S, Tariq R et al. Increasing antibiotic resistance in Clostridioides difficile: a systematic review and meta-analysis. Anaerobe 2019; 58: 35–46.

38 Glass-Kaastro SK, Finley R, Hutchinson J et al. Variation in outpatient oral antimicrobial use patterns among Canadian provinces, 2000 to 2010. Can J Infect Dis Med Microbiol 2014; 25: 95–8.

39 Cadieux G, Tamblyn R. Accuracy of physician billing claims for identifying acute respiratory infections in primary care. Health Serv Res 2008; 43: 2223–38.